Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.
about
Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical TrialsPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseA pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.AMPK activation: a therapeutic target for type 2 diabetes?Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Extra-pancreatic effects of incretin-based therapies.Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Use of and Beliefs About Mobile Phone Apps for Diabetes Self-Management: Surveys of People in a Hospital Diabetes Clinic and Diabetes Health Professionals in New Zealand.Sitagliptin: A Review in Type 2 Diabetes.Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats.Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
P2860
Q26772068-F7FC45E2-8465-42CE-B985-6EBA89E66104Q27027920-AC9D362D-5FFE-4BAC-BA35-AD8959F75ACEQ33726648-69961F92-EEBD-436C-92B9-8486F6DB7B7AQ33824564-BA2F6C26-F4C1-43C4-9E93-D69E01F69B32Q35538305-9A9C393D-AD57-47BE-BA11-592D973D6566Q36335898-D252E9D6-283E-4F4D-B282-9048A29E5CEFQ36354599-2752F677-F83A-464D-95E1-9370504EF122Q37101005-116A36F7-5B56-4103-A6F0-0B4FCECD0A87Q37696575-CF560778-F048-4B58-862C-28508000FE53Q38177173-4FC537ED-ACD4-4CC4-96A8-ED4F10D791CAQ38194069-6CB730BB-C35E-4822-A73D-9153F1B4682EQ38198185-9C830A3A-17C0-47C9-A698-BB471830051BQ38200670-FD4CE9AF-00A1-46D4-91B0-552F8CA0C007Q38255715-1F7367C4-6034-4283-8F3F-699F31468D6DQ38258278-D900EB93-9295-4DF8-BED3-6E7194944E1BQ38412153-FE8DBA18-7EE4-470F-8AF2-29E9B1FEB369Q38527885-30C10D8D-F997-4857-BD9B-F83E18C48CF0Q38644587-44635BEC-1B5F-46A9-8F56-468687852365Q38645792-32ECC6B7-B058-4423-87A0-1927EF6BBC72Q38664296-0FACBA43-F228-47C6-8F31-462E545EA570Q39081543-7BE1C880-3148-47DD-9A07-D0F3BAB1533BQ41449397-AFCA4C94-263C-49A4-ABC3-E61A9A10FB9FQ42872673-F9854BC4-E91F-430D-9038-41E325CB628AQ47766606-0C4A3CCA-ACEA-4765-A16E-68E133AAA702Q48108721-70BF86B4-501E-40E9-9020-A25FCBB0AA29Q48379621-D233624E-469E-4699-8348-F3CC0CA0F736Q50121585-C05BA8F4-CE15-4F82-B0E7-2B2E8FB89092Q50348623-712B0693-511A-4C9B-9A85-2CADDE6EDA39Q55163277-7FF4CE69-2032-4E88-A253-6EBBBC15B476
P2860
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dipeptidyl peptidase-4 inhibit ...... mparison, efficacy and safety.
@en
type
label
Dipeptidyl peptidase-4 inhibit ...... mparison, efficacy and safety.
@en
prefLabel
Dipeptidyl peptidase-4 inhibit ...... mparison, efficacy and safety.
@en
P2860
P1476
Dipeptidyl peptidase-4 inhibit ...... mparison, efficacy and safety.
@en
P2860
P304
P356
10.1517/14656566.2013.824966
P407
P577
2013-08-07T00:00:00Z